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Abstract
Purpose of Review Hepatic encephalopathy (HE) is a common and devastating complication to chronic liver disease. In this
paper, we summarize the latest research and evidence of both conventional and up-coming treatments.
Recent Findings Meta-analyses report beneficial effects of lactulose, branched-chain amino acids, rifaximin, and to some degree
L-ornithine L-aspartate on the manifestations of HE in patients with cirrhosis, and generally the numbers needed to treat are low.
Recent studies on newer HE treatments including ornithine phenylacetate, spherical carbon, and fecal microbiota transplant also
report potentially beneficial effects on HE manifestations.
Summary The conventional treatments benefit patients with HE. Newer treatments are under study and more research is needed
for their validation.
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Introduction
Hepatic encephalopathy (HE) is a common complication of
advanced liver disease. HE covers a complex set of non-
specific neuropsychiatric symptoms and clinical signs
affecting quality of life of both patients and their relatives.
Due to frequent hospital contacts and admissions, HE is a
major challenge to the healthcare system.
The pathophysiology of HE is not fully understood, but the
condition reflects a diffuse disturbance of brain functions due
to advanced liver disease or large portosystemic shunts
(PSSs). The 2014 AASLD and EASL clinical practice guide-
lines for managing HE recommend classifying HE according
to the underlying liver disease, the severity of the manifesta-
tions, the time course, and precipitating factors. HE may be
divided into type A resulting from acute liver failure, type B
resulting predominantly from PSS, and type C resulting from
cirrhosis [1••]. Type C is by far the most predominant. HE
describes a wide range of manifestations from minimal HE
(MHE) over overt HE (OHE) to frank coma. OHE is present
in 10–14% of patients at the time of diagnosis of cirrhosis. The
5-year risk of the first bout of OHEmay be as high as 25%.Up
to 40% of patients with cirrhosis will experience at least one
episode; many will experience repeated episodes. MHE is
diagnosed in 20–80% of patients with cirrhosis [2–6]. The
1-year incidence of type B OHE in patients with a transjugular
intrahepatic portosystemic shunt (TIPS) is estimated to be
10–50% [7, 8]. HE is a very poor prognostic factor with a
1-year mortality of 54–85% [4, 9].
The initial treatment of patients with HE is directed at
precipitating factors, present in at least 50%, and at general
correction, stabilization, and nutrition. Several specific medi-
cal treatments against HE are available; most involve lowering
of blood ammonia levels. This review provides an updated
overview of the conventional and new drugs and principles
for the treatment of HE (Table 1).
Old “Drugs,” New Evidence
Lactulose
The non-absorbable disaccharide lactulose (and lactitol) is the
first-line treatment for HE [10]. Acting as both osmotic laxa-
tive, prebiotic, and gut acidifying agent, lactulose causes
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several beneficial effects by both reducing the production and
the absorption of ammonia from the intestines by changing the
gut microbiota [11]. A 2016 updated Cochrane review found
31 randomized controlled trials investigating the treatment of
HE, while 7 looked at HE prevention. Compared to placebo/
no intervention, lactulose had a beneficial effect on HE with
numbers needed to treat (NNT) of only four patients reflecting
a marked relative risk reduction to 0.63. Lactulose had bene-
ficial effects on both OHE and MHE, as well episodic as
recurrent HE prevention, and also on the risk of serious ad-
verse events such as liver failure, variceal bleeding, spontane-
ous bacterial peritonitis, hepatorenal syndrome, and ultimately
on mortality [12••]. Lactulose is associated with only non-
serious and mostly transient adverse events. Finally, lactulose
is available all places and is very cheap. Thus, lactulose is now
further established as the mainstay of prevention and treat-
ment of all manifestations of HE.
Branched-Chain Amino Acids
In cirrhosis, plasma levels of branched-chain amino acids
(BCAAs: leucine, isoleucine, valine) are decreased as part of
a general amino acid dyshomeostasis. There is increasing ev-
idence for BCAAs being beneficial in HE, but the mechanism
seems to be different from the originally assumed excitatory
effect on neurotransmission. The effect is rather ammonia de-
toxification outside the liver via effects on skeletal muscle
protein synthesis. Ammonia decreases protein synthesis by
impairing the mTOR signaling, an effect counteracted by
BCAAs [13].
A 2016 Cochrane review on the effects of BCAAs on HE
in cirrhosis [14•] included 16 RCTs comprising 827
participants with HE classed as OHE (12 trials) or MHE
(four trials). Eight trials assessed oral BCAA supplements,
and seven trials assessed intravenous BCAAs. The control
groups received placebo/no intervention (two trials), diets
(ten trials), lactulose (two trials), or neomycin (two trials).
The meta-analyses showed that BCAAs have a beneficial
effect on HE manifestations with a NNTof five patients and a
relative risk reduction to 0.73. BCAAs had no effect on
mortality.
The evidence shows that oral but not intravenous BCAAs
have the beneficial effects. In sarcopenic patients with cirrho-
sis, the muscle build-up resulting from BCAAs, besides con-
tributing to the effect on HE, carries important improvements
in daily living and quality of life.
L-Ornithine L-Aspartate
L-Ornithine L-Aspartate (LOLA) is the stable salt of the amino
acids ornithine and aspartate. By at the same time providing
metabolic substrates for urea cycle in liver and glutamine syn-
thesis in skeletal muscle, LOLA stimulates ammonia detoxi-
fication and lowers blood ammonia [15]. A 2017 RCT com-
pared the effect of intravenous LOLA versus placebo in
reverting OHE at day 5 of treatment in a total of 193 patients
with cirrhosis. The authors conclude that LOLA shortens the
recovery time from OHE and the duration of hospitalization
[16]. A meta-analysis of LOLA versus placebo or other inter-
ventions (lactulose, probiotics, and/or rifaximin) included
26 RCTs involving 1783 patients [17]. LOLA had a beneficial
effect on HE (RR 0.60, 95%CI 0.44–0.82) and was associated
with reduced mortality (RR 0.42, 95% CI 0.22–0.84).
However, the data were highly selected and available for only
65% of eligible participants. Thus, the evidence for a benefi-
cial effect of LOLA is weak. A definitive Cochrane review is
underway.
Non-absorbable Antibiotics
Antibiotics with activity against urease-producing gut bacteria
have an ammonia-lowering effect. These include neomycin,
paromomycin, metronidazole, vancomycin, and rifaximin.
Rifaximin today is by far most commonly used owing to its
low systemic absorption, broad antimicrobial spectrum, and
low frequency of side effects [18]. The best evidence for the
utility of rifaximin is the large 2010 RCT published in NEJM,
where the drug as an add-on to patients with HE break-
through despite correct lactulose treatment effectively
protected against OHE recurrence [19•]. A 2014 review and
meta-analysis of rifaximin versus placebo or other interven-
tions (lactulose or other antibiotics) included 19 RCTs with a
total of 1370 patients. Rifaximin had a beneficial effect on
recovery from HE (RR 0.59; 95% CI 0.46–0.76), on second-
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mortality (RR 0.68, 95% CI 0.48–0.97). The NNT was four
patients [20]. Some of the included studies are small, but the
results seem to be robust to bias control. Thus, rifaximin has a
place mostly in prevention of recurrence of HEwhen lactulose
alone fails. However, the accessibility of rifaximin may be
limited by its high cost. Both neomycin and metronidazole
have been used alone or as add-on to lactulose to treat HE.
Generally, the studies are old and of low quality [19•, 21, 22].
Additionally, these antibiotics have serious side effects; neo-
mycin causes nephrotoxicity, ototoxicity, and malabsorption;
metronidazole causes irreversible peripheral neurotoxicity.
Prolonged use is thus not recommended.
Albumin
In advanced liver disease, the albumin production is reduced.
Additionally, the albumin molecule may have decreased bind-
ing capacity and detoxification capacity [23–25]. The mecha-
nism of action of albumin infusion in HE may be a combina-
tion of decreased oxidative stress and improved circulatory
function. Few trials studied the effect of albumin on HE. A
narrative review from 2015 suggested that albumin may have
beneficial effects on HE recovery and mortality [26]. Albumin
dialysis may also play an important role in improving HE in
patients not responding to the best standard of care. In addi-
tion, an open-label RCT found beneficial effects of albumin as
an add-on to lactulose on HE manifestations, the length of
hospitalization, and mortality [27]. However, the trial was
small and the results should be verified before any clinical
conclusions can be made.
Flumazenil
The role of flumazenil in the therapeutic management of HE is
thought to be a reduction in the activity of the neuroinhibitory
GABA/benzodiazepine receptor complex, countering the
overall neural inhibition in HE [28]. A 2017 Cochrane meta-
analysis concludes that flumazenil seems to have some short-
term (minutes) beneficial effect on HE, but there is no evi-
dence of effect on recovery, overall mortality, or health-related
quality of life [29]. Flumazenil has no role in HE diagnostics.
Hyperalimentation
The resting metabolic rate relative to lean body mass is often
increased in patients with cirrhosis, which may contribute to
their frequent malnutrition and sarcopenia [30, 31]. The pa-
tients exhibit reduced hepatic glycogen storage resulting in a
faster switch to (obligatory) gluconeogenesis from amino
acids and lipolysis when after a short period of fasting [32].
This consumption of blood amino acids promotes proteolysis,
skeletal muscle wasting, increased dietary protein require-
ments, and increased ammonia production [33]. The 2013
International Society for Hepatic Encephalopathy and
Nitrogen Metabolism guidelines for nutrition of HE patients
[34] recommend a daily energy intake of 35–40 kcal/kg body
weight including 1.2–1.5 g protein/kg body weight (best re-
lated to ascites-free body weight) for the maintenance and
improvement of nutritional status. HE patients should eat
small frequent meals evenly distributed during the day includ-
ing a late night snack and avoid fasting for longer than 3–6 h
during daytime. As mentioned above, coverage of some of the
patients’ high-protein needs with BCAAs can have specific
beneficial effects on sarcopenia and HE. Former times’ rec-
ommendation of low-protein diet to HE patients is definitively
shown to be obsolete and harmful in increasing the risk for HE
as well as for catabolism and risk for cirrhosis complications.
New “Drugs,” New Evidence
Ammonia-Lowering Agents
Ornithine phenylacetate (OPA), phenylbutyrate (PB), and
benzoate act as ammonia scavengers by binding ammonia
by their metabolism, leading to elimination of nitrogen by
urinary non-urea excretion [35, 36].
OPA stimulates glutamine synthetase and thereby the for-
mation of ammonia to glutamine. Glutamine subsequently
combines with phenylacetate into phenylacetylglutamine
(PAGN), eliminated in the urine [37]. A phase 2a study includ-
ing 47 patients with acute liver injury or failure found OPA to
be safe and well tolerated [38]. In agreement with previous
findings, the study also suggests OPA to have a potential for
dose-dependent ammonia lowering [39, 40]. There is at present
no clinical evidence of a significant HE-ameliorating effect.
PB, a pro-drug of phenylacetate, also increases ammonia
excretion in urine in the form of PAGN. A phase II RCT
suggests that PB may lower ammonia and reduce the risk of
new episodes of HE and hospitalizations in patients with ear-
lier HE [41]. A preliminary study on PB to HE patients on
intensive care unit indicated that PB might lower ammonia
and improve HE status [42]. Presently, there is no definitive
evidence of a significant HE-ameliorating effect.
Benzoate eliminates ammonia by conjugation with glycine
to form hippurate, eliminated in urine [43, 44]. The drug is
cheap and has few side effects. It is a time-honored remedy of
congenital urea cycle defects. One small CRT found a com-
parable effect of sodium benzoate and lactulose in treating HE
in patients with cirrhosis [44]. The drug is not established in
the clinical management of HE but deserves further trials.
Spherical Carbon (AST-120)
This is an orally administered, engineered carbon microsphere
that adsorbs ammonia and other organic compounds from the
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gastrointestinal tract. In bile duct ligated rats, it lowers ammo-
nia and decreases oxidative stress and brain edema [45].
Preliminary human studies report potential ammonia-
lowering and cognitive benefits [46, 47].
GABAA Receptor Modulating Steroid Antagonists
A study on patients with cirrhosis andHEwho died [48] found
increased brain contents of neurosteroids. These increase
activity in the strongly neuroinhibitory GABA system.
Likewise, the brain of rats with chronic HE shows an
increased GABAergic tone [49].
GABAA receptor modulating steroid antagonists
(GAMSAs) act as antagonists to the positive GABAA recep-
tor, decreasing the effects of the neurosteroids [48]. This ben-
efits arousal, cognition, and consciousness of patients with HE
[50]. GAMSAs are shown to have positive effects on learning
impairment in rats with experimental HE [51]. They also re-
store motor coordination, spatial learning, and memory in the
rats [52]. The drug has successfully passed human safety trials
and is now under clinical evaluation in cirrhosis patients with
HE [50].
Fecal Microbiota Transplant
Patients with cirrhosis tend to have a reduced abundance of
several potentially beneficial bacterial families, including
Lachnospiraceae and Ruminococcaceae, and an increased
abundance of the pathogenic Enterobacteriaceae and
Streptococcaceae [53, 54]. An open-label, randomized pilot
trial on patients with recurrent HE compared the safety of fecal
microbiota transplant (FMT) (from one donor matched to the
dysbiosis in HE) versus no such intervention [55]. As a sec-
ondary trial outcome, the FMTwas associatedwith fewer liver-
related hospitalizations and improved cognitive function.
Probiotics
Probiotics contain live microorganisms with expected benefi-
cial effects on the gut dysbiosis and increased ammonia pro-
duction in patients with cirrhosis and HE [56]. A Cochrane
review concluded that probiotics may lower ammonia and im-
prove recovery from HE and better the quality of life, but there
was no clear improvement of overall mortality. However, most
trials were of low quality with a high risk of systematic and
random errors [57]. A comparison of the treatment effect of
probiotics and the prebiotic lactulose was hence not possible.
Other Treatments
Large portosystemic shunts (PSSs) may cause recurrent or
persistent HE in patients with cirrhosis refractory to medical
treatment. Embolization of the PSSs has been performed to
improve HE in carefully selected patients, and a few retro-
spective studies are published within the last few years. A
multicenter survey on 37 such patients showed more than
half of the patients to be free of HE within 100 days of
embolization and nearly half remained so for 2 years [58].
Similarly, a retrospective report [59] on 20 similar patients
found that at all patients self-described sustained HE im-
provement; many of them could reduce or discontinue their
anti-HE treatment, but about half had to continue their med-
ical treatment. Thus, PSS embolization may be a treatment
option in selected cases of persistent HE and complications
to the ensuing portal hypertension such as esophageal var-
ices allowing.
Liver transplantation represents the ultimate and in a way
the only causal treatment of HE in patients with liver failure.
Following transplantation, most patients are free of HE, but
careful follow-up studies emphasize that some cognitive im-
pairment may persist [60–63]. HE in itself is not considered an
indication for transplantation.
Conclusions
Until recently, the treatment of HE was rooted in strategies
based upon personal experience, drug availability, and tradi-
tion in the respective hospital settings. As more RCTs are
being performed and reported, more solid evidence is building
up in support of marked beneficial effects of the conventional
HE treatment strategies (lactulose, branched-chain amino
acids, rifaximin) and confirms their central role in the specific
HE treatment. Embolization of large PSSs and liver transplan-
tation are efficient treatments in few and highly selected
patients.
Additionally, newer and promising treatments are currently
studied in experimental and clinical settings, but more evi-
dence is needed before these treatments will earn a place in
the routine HE treatment strategy. However, no revolutionary
or causal treatment strategies have been introduced, probably
due to the fact that the HE pathogenesis is still not fully
understood.
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